

List of Publications by Year in
Descending Order

Source: <https://exaly.com/author-pdf/8539396/marc-g-ghany-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

179 papers	16,677 citations	61 h-index	128 g-index
199 ext. papers	18,920 ext. citations	9.4 avg, IF	6.98 L-index

#	Paper	IF	Citations
179	Review article: hepatitis B-current and emerging therapies.. <i>Alimentary Pharmacology and Therapeutics</i> , 2022 ,	6.1	0
178	Letter to the Editor: HBcrAg and Prediction of Hepatocellular Carcinoma Risk. <i>Hepatology</i> , 2021 ,	11.2	
177	Systematic review with meta-analysis: the impact of functional cure on clinical outcomes in patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 ,	6.1	2
176	Spontaneous Clearance of Drug-Resistant Chronic Hepatitis C Virus Infection. <i>Hepatology</i> , 2021 , 74, 3552-3553	11.2	1
175	Fatty Liver Disease in a Prospective North American Cohort of Adults With Human Immunodeficiency Virus and Hepatitis B Virus Coinfection. <i>Clinical Infectious Diseases</i> , 2021 , 73, e3275-e3285	11.6	4
174	Liver Disease and Coronavirus Disease 2019: From Pathogenesis to Clinical Care. <i>Hepatology</i> , 2021 , 74, 1088-1100	11.2	22
173	The 2020 Nobel Prize for Medicine or Physiology for the Discovery of Hepatitis C Virus: A Triumph of Curiosity and Persistence. <i>Hepatology</i> , 2021 , 74, 2813-2823	11.2	1
172	Clearance of pegylated interferon by Kupffer cells limits NK cell activation and therapy response of patients with HBV infection. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	5
171	Hepatic Steatosis and Steatohepatitis in a Large North American Cohort of Adults With Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2021 , 116, 1686-1697	0.7	4
170	Liver disease symptoms are associated with higher risk of adverse clinical outcomes: A longitudinal study of North American adults with chronic Hepatitis B. <i>GastroHep</i> , 2021 , 3, 196-208	1	
169	Clinical significance of quantitative e antigen in a cohort of hepatitis B virus-infected children and adults in North America. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 1042-1056	3.4	2
168	Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy. <i>Hepatology</i> , 2021 , 73, 2124-2140	11.2	8
167	Precore and Basal Core Promoter Hepatitis B Virus (HBV) Variants Are Present From a Young Age and Differ Across HBV Genotypes. <i>Hepatology</i> , 2021 , 73, 1637-1651	11.2	4
166	Randomized Trial of a Vaccine Regimen to Prevent Chronic HCV Infection. <i>New England Journal of Medicine</i> , 2021 , 384, 541-549	59.2	25
165	Performance of Serum-Based Scores for Identification of Mild Hepatic Steatosis in HBV Mono-infected and HBV-HIV Co-infected Adults. <i>Digestive Diseases and Sciences</i> , 2021 , 1	4	2
164	A Prospective Study Evaluating Changes in Histology, Clinical and Virologic Outcomes in HBV-HIV Co-infected Adults in North America. <i>Hepatology</i> , 2021 , 74, 1174-1189	11.2	2
163	Prospective Study of Withdrawal of Antiviral Therapy in Patients with Chronic Hepatitis B after Prolonged Virological Response. <i>Hepatology Communications</i> , 2021 , 5, 1888-1900	6	1

162	Hepatitis B e antigen loss in adults and children with chronic hepatitis B living in North America: A prospective cohort study. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 1526-1538	3.4	0
161	Comparison of HBV RNA and Hepatitis B Core Related Antigen With Conventional HBV Markers Among Untreated Adults With Chronic Hepatitis B in North America. <i>Hepatology</i> , 2021 , 74, 2395-2409	11.2	5
160	Alcohol, tobacco and coffee consumption and liver disease severity among individuals with Chronic Hepatitis B infection in North America. <i>Annals of Hepatology</i> , 2020 , 19, 437-445	3.1	2
159	Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 406-417	18.8	22
158	Viral Escape Mechanisms in Hepatitis C and the Clinical Consequences of Persistent Infection 2020 , 868-888		
157	Defective glycosylation and multisystem abnormalities characterize the primary immunodeficiency XMEN disease. <i>Journal of Clinical Investigation</i> , 2020 , 130, 507-522	15.9	42
156	Hepatitis B: Current Status of Therapy and Future Therapies. <i>Gastroenterology Clinics of North America</i> , 2020 , 49, 215-238	4.4	19
155	Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B. <i>Hepatology Communications</i> , 2020 , 4, 8-20	6	18
154	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. <i>Journal of Hepatology</i> , 2020 , 72, 539-557	13.4	88
153	Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. <i>Hepatology</i> , 2020 , 71, 686-721	11.2	236
152	Hepatic Histology in Treatment-naïve Children With Chronic Hepatitis B Infection Living in the United States and Canada. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2020 , 71, 99-105	2.8	2
151	Evaluating Noninvasive Markers to Identify Advanced Fibrosis by Liver Biopsy in HBV/HIV Co-infected Adults. <i>Hepatology</i> , 2020 , 71, 411-421	11.2	17
150	Durability of Spontaneous and Treatment-Related Loss of Hepatitis B s Antigen. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 700-709.e3	6.9	17
149	Hepatitis B and C virus infection and risk of haematological malignancies. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 4-12	3.4	5
148	Longitudinal effects of Nucleos(t)ide analogue therapy in chronic hepatitis B patients and the utility of non-invasive fibrosis markers during treatment: A single-center experience for up to 17 years. <i>Antiviral Research</i> , 2019 , 168, 61-67	10.8	2
147	Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 856-865	3.4	11
146	Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2541-2551.e2	6.9	15
145	WHO Guidelines for Prevention, Care and Treatment of Individuals Infected with HBV: A US Perspective. <i>Clinics in Liver Disease</i> , 2019 , 23, 417-432	4.6	17

144	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. <i>Hepatology</i> , 2019 , 71, 1070	11.2	23
143	Phase Transition Is Infrequent Among North American Adults With e-Antigen-Negative Chronic Hepatitis B and Low-Level Viremia. <i>American Journal of Gastroenterology</i> , 2019 , 114, 1753-1763	0.7	5
142	Spectrum of Liver Disease in Hepatitis B Virus (HBV) Patients Co-infected with Human Immunodeficiency Virus (HIV): Results of the HBV-HIV Cohort Study. <i>American Journal of Gastroenterology</i> , 2019 , 114, 746-757	0.7	16
141	Entecavir and Peginterferon Alfa-2a in Adults With Hepatitis B e Antigen-Positive Immune-Tolerant Chronic Hepatitis B Virus Infection. <i>Hepatology</i> , 2019 , 69, 2338-2348	11.2	14
140	Baseline Intrahepatic and Peripheral Innate Immunity are Associated with Hepatitis C Virus Clearance During Direct-Acting Antiviral Therapy. <i>Hepatology</i> , 2018 , 68, 2078-2088	11.2	26
139	Disease Pathways and Mechanisms of Potential Drug Targets. <i>Clinical Liver Disease</i> , 2018 , 12, 12-18	2.2	4
138	Hepatitis C Guidance 2018 Update: AASLD-IDS Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , 2018 , 67, 1477-1492	11.6	344
137	Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFN- γ . <i>Gut</i> , 2017 , 66, 724-735	19.2	46
136	Prospective phenotyping of NGLY1-CDDG, the first congenital disorder of deglycosylation. <i>Genetics in Medicine</i> , 2017 , 19, 160-168	8.1	72
135	Complications of percutaneous liver biopsy with Klatzkin needles: a 36-year single-centre experience. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 744-753	6.1	35
134	Current treatment guidelines of chronic hepatitis B: The role of nucleos(t)ide analogues and peginterferon. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2017 , 31, 299-309	2.5	41
133	Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 1032-1042	3.4	9
132	Characteristics of US-Born Versus Foreign-Born Americans of African Descent With Chronic Hepatitis B. <i>American Journal of Epidemiology</i> , 2017 , 186, 356-366	3.8	7
131	Determination of hepatitis B phenotype using biochemical and serological markers. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 320-329	3.4	34
130	NAM 2017 report: A national plan to eliminate hepatitis B and C in the United States by 2030 and the AASLD's response. <i>Hepatology</i> , 2017 , 66, 1020-1022	11.2	7
129	Hepatitis B cure: From discovery to regulatory approval. <i>Journal of Hepatology</i> , 2017 , 67, 847-861	13.4	123
128	Hepatitis B cure: From discovery to regulatory approval. <i>Hepatology</i> , 2017 , 66, 1296-1313	11.2	150
127	Intra-Hepatic Depletion of Mucosal-Associated Invariant T Cells in Hepatitis C Virus-Induced Liver Inflammation. <i>Gastroenterology</i> , 2017 , 153, 1392-1403.e2	13.3	57

126	Cellular microRNA networks regulate host dependency of hepatitis C virus infection. <i>Nature Communications</i> , 2017 , 8, 1789	17.4	44
125	Hepatitis B and D 2017 , 584-627		
124	Hepatitis E Virus Does Not Contribute to Hepatic Decompensation Among Patients With Advanced Chronic Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 896-902	6.9	5
123	Hepatitis B Virus--Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. <i>Gastroenterology</i> , 2016 , 150, 684-695.e5	13.3	126
122	Should Family Physicians Routinely Screen Patients for Hepatitis C? Yes: Screening Makes Sense for High-Risk Adults. <i>American Family Physician</i> , 2016 , 93, 15-6	1.3	
121	Natural History of Chronic Hepatitis C 2016 , 3-55		1
120	Long-term lamivudine therapy in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 380-9	6.1	11
119	Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function. <i>Gastroenterology</i> , 2015 , 149, 190-200.e2	13.3	181
118	An Epidemiologic Investigation of a Case of Acute Hepatitis E. <i>Journal of Clinical Microbiology</i> , 2015 , 53, 3547-52	9.7	10
117	Natural History of Hepatitis C. <i>Gastroenterology Clinics of North America</i> , 2015 , 44, 717-34	4.4	121
116	Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 183-92	6.9	68
115	Durability of antibody response against hepatitis B virus in healthcare workers vaccinated as adults. <i>Clinical Infectious Diseases</i> , 2015 , 60, 505-13	11.6	36
114	Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. <i>Hepatology</i> , 2015 , 62, 932-54	11.2	968
113	Screening for hepatitis B virus to prevent viral reactivation - who and when?. <i>Clinical Liver Disease</i> , 2015 , 5, 47-50	2.2	5
112	Present and future therapies of hepatitis B: From discovery to cure. <i>Hepatology</i> , 2015 , 62, 1893-908	11.2	211
111	Diabetes and prediabetes in patients with hepatitis B residing in North America. <i>Hepatology</i> , 2015 , 62, 1364-74	11.2	19
110	QUEST for a cure for hepatitis C virus: the end is in sight. <i>Lancet, The</i> , 2014 , 384, 381-3	4.0	6
109	Long-term therapy of chronic delta hepatitis with peginterferon alfa. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 40, 93-104	6.1	61

108	Reply: To PMID 23703931. <i>Hepatology</i> , 2014 , 59, 1651	11.2	1
107	Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. <i>Gut</i> , 2014 , 63, 161-9	19.2	48
106	Spontaneous Mutations in the HBV Genome and their Clinical Implications. <i>Current Hepatitis Reports</i> , 2013 , 12, 79-87		1
105	The hepatitis B vaccine protects re-exposed health care workers, but does not provide sterilizing immunity. <i>Gastroenterology</i> , 2013 , 145, 1026-34	13.3	37
104	Hepatitis B virus treatment: Management of antiviral drug resistance. <i>Clinical Liver Disease</i> , 2013 , 2, 24-28.2		5
103	Hepatitis E: The nonendemic perspective. <i>Clinical Liver Disease</i> , 2013 , 2, 245-249	2.2	1
102	Discordance among transient elastography, aspartate aminotransferase to platelet ratio index, and histologic assessments of liver fibrosis in patients with chronic hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2013 , 11, 303-8.e1	6.9	23
101	The liver diseases of lipodystrophy: the long-term effect of leptin treatment. <i>Journal of Hepatology</i> , 2013 , 59, 131-7	13.4	118
100	Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 37, 887-94	6.1	40
99	Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. <i>Hepatology</i> , 2013 , 58, 1548-57	11.2	89
98	Acute hepatitis C: to treat or not to treat. <i>Lancet Infectious Diseases, The</i> , 2013 , 13, 467-8	25.5	1
97	Current and future therapies for hepatitis C virus infection. <i>New England Journal of Medicine</i> , 2013 , 368, 1907-17	59.2	355
96	What the infectious disease physician needs to know about pegylated interferon and ribavirin. <i>Clinical Infectious Diseases</i> , 2013 , 56, 1629-36	11.6	20
95	Current and future therapies for hepatitis C virus infection. <i>New England Journal of Medicine</i> , 2013 , 369, 679-80	59.2	39
94	Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 1317-25	6.1	113
93	Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series. <i>Digestive Diseases and Sciences</i> , 2012 , 57, 2423-9	4	91
92	Randomised clinical trial: the benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 1027-35	6.1	19
91	The new standard of HCV therapy: Retreatment in experienced patients. <i>Clinical Liver Disease</i> , 2012 , 1, 16-19	2.2	

90	Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C. <i>American Journal of Gastroenterology</i> , 2012 , 107, 1388-98	0.7	14
89	A 25-year study of the clinical and histologic outcomes of hepatitis C virus infection and its modes of transmission in a cohort of initially asymptomatic blood donors. <i>Journal of Infectious Diseases</i> , 2012 , 206, 654-61	7	24
88	The application and mechanism of action of ribavirin in therapy of hepatitis C. <i>Antiviral Chemistry and Chemotherapy</i> , 2012 , 23, 1-12	3.5	77
87	S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders. <i>Gastroenterology</i> , 2011 , 140, 830-9	13.3	40
86	Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. <i>Gastroenterology</i> , 2011 , 140, 840-9; quiz e12	13.3	162
85	Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. <i>Hepatology</i> , 2011 , 53, 1100-8	11.2	44
84	A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. <i>Hepatology</i> , 2011 , 54, 396-405	11.2	121
83	Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial. <i>Hepatology</i> , 2011 , 54, 1527-37	11.2	23
82	An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2011 , 54, 1433-44	11.2	854
81	Development and progression of portal hypertensive gastropathy in patients with chronic hepatitis C. <i>American Journal of Gastroenterology</i> , 2011 , 106, 884-93	0.7	8
80	Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 31, 719-34	6.1	21
79	Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 31, 1018-27	6.1	6
78	Hepatitis C progressing to hepatocellular carcinoma: the HCV dialysis patient in dilemma. <i>Journal of Viral Hepatitis</i> , 2010 , 17, 59-64	3.4	15
77	Management of untreated and nonresponder patients with chronic hepatitis C. <i>Seminars in Liver Disease</i> , 2010 , 30, 348-60	7.3	3
76	Hepatitis B virology for clinicians. <i>Clinics in Liver Disease</i> , 2010 , 14, 397-408	4.6	16
75	Pharmacokinetics and pharmacodynamics of peginterferon and ribavirin: implications for clinical efficacy in the treatment of chronic hepatitis C. <i>Gastroenterology Clinics of North America</i> , 2010 , 39, 649-58	4.4	20
74	Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. <i>Gastroenterology</i> , 2010 , 138, 325-35.e1-2	13.3	211
73	Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. <i>Gastroenterology</i> , 2010 , 138, 136-46	13.3	76

72	Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C. <i>Gastroenterology</i> , 2010 , 138, 2321-31, 2331.e1-2	13.3	32
71	Ribavirin improves early responses to peginterferon through improved interferon signaling. <i>Gastroenterology</i> , 2010 , 139, 154-62.e4	13.3	100
70	Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. <i>Clinical Gastroenterology and Hepatology</i> , 2010 , 8, 877-83	6.9	292
69	Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. <i>Hepatology</i> , 2010 , 51, 585-94	11.2	109
68	Outcome of sustained virological responders with histologically advanced chronic hepatitis C. <i>Hepatology</i> , 2010 , 52, 833-44	11.2	373
67	Diagnosis, management, and treatment of hepatitis C: an update. <i>Hepatology</i> , 2009 , 49, 1335-74	11.2	2284
66	Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. <i>Hepatology</i> , 2009 , 49, 1828-37	11.2	46
65	Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. <i>Hepatology</i> , 2009 , 49, 1847-58	11.2	67
64	Antiviral resistance and hepatitis B therapy. <i>Hepatology</i> , 2009 , 49, S174-84	11.2	166
63	Human immunodeficiency virus and hepatitis C infections induce distinct immunologic imprints in peripheral mononuclear cells. <i>Hepatology</i> , 2009 , 50, 34-45	11.2	42
62	Reply:. <i>Hepatology</i> , 2009 , 50, 324-325	11.2	3
61	Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. <i>Hepatology</i> , 2009 , 50, 1360-9	11.2	124
60	Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial. <i>Hepatology</i> , 2009 , 50, 1738-49	11.2	55
59	Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. <i>Gastroenterology</i> , 2009 , 136, 138-48	13.3	481
58	Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. <i>Gastroenterology</i> , 2009 , 137, 549-57	13.3	106
57	Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. <i>Gastroenterology</i> , 2009 , 137, 1986-94	13.3	29
56	Management of Antiviral Resistance in Chronic Hepatitis B 2009 , 273-287		
55	DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. <i>Journal of Hepatology</i> , 2008 , 49, 548-56	13.4	41

54	Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2008 , 6, 234-41	6.9	23
53	Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. <i>New England Journal of Medicine</i> , 2008 , 359, 2429-41	59.2	379
52	Association between body mass index and diabetes and hepatocellular carcinoma. <i>Annals of Internal Medicine</i> , 2008 , 148, 166-7; author reply 167	8	2
51	Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. <i>Hepatology</i> , 2008 , 47, 605-12	11.2	100
50	Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C. <i>Hepatology</i> , 2008 , 48, 1412-9 ^{11.2}	11.2	17
49	Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. <i>Clinical Gastroenterology and Hepatology</i> , 2007 , 5, 245-54	6.9	40
48	Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. <i>Gastroenterology</i> , 2007 , 132, 103-12	13.3	173
47	Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. <i>Gastroenterology</i> , 2007 , 132, 1574-85	13.3	142
46	Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. <i>Gastroenterology</i> , 2007 , 132, 1757-66	13.3	92
45	Two cases of thyroid storm-associated cholestatic jaundice. <i>Endocrine Practice</i> , 2007 , 13, 476-80	3.2	41
44	Myxovirus-1 and protein kinase haplotypes and fibrosis in chronic hepatitis C virus. <i>Hepatology</i> , 2007 , 46, 74-83	11.2	11
43	The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2007 , 46, 424-9	11.2	193
42	Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. <i>Hepatology</i> , 2007 , 46, 254-65	11.2	377
41	Evolution of therapy for chronic hepatitis B: progressing from the simple to the complex. <i>Annals of Internal Medicine</i> , 2007 , 147, 806-8	8	3
40	Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. <i>Journal of Hepatology</i> , 2007 , 46, 420-31	13.4	112
39	Natural history of hbeag-negative chronic Hepatitis b. <i>Current Hepatitis Reports</i> , 2006 , 5, 27-32		
38	Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. <i>Hepatology</i> , 2006 , 43, 780-7	11.2	61
37	HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. <i>Hepatology</i> , 2006 , 44, 360-7	11.2	41

36	Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection. <i>Hepatology</i> , 2006 , 44, 925-35	11.2	48
35	Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. <i>Hepatology</i> , 2006 , 44, 1675-84	11.2	131
34	Portal hypertensive gastropathy in chronic hepatitis C patients with bridging fibrosis and compensated cirrhosis: results from the HALT-C trial. <i>American Journal of Gastroenterology</i> , 2006 , 101, 983-92	0.7	52
33	Efforts to define the natural history of chronic hepatitis C continue. <i>Clinical Gastroenterology and Hepatology</i> , 2006 , 4, 1190-2	6.9	3
32	Assessment and management of chronic hepatitis B. <i>Infectious Disease Clinics of North America</i> , 2006 , 20, 63-79	6.5	5
31	Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. <i>Clinical Gastroenterology and Hepatology</i> , 2006 , 4, 1048-52	6.9	79
30	Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. <i>Gastroenterology</i> , 2006 , 131, 1440-51	13.3	74
29	The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis. <i>Gastrointestinal Endoscopy</i> , 2006 , 64, 855-64	5.2	85
28	Pilot study of interferon gamma for chronic hepatitis C. <i>Journal of Hepatology</i> , 2005 , 43, 67-71	13.4	28
27	Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. <i>Journal of Hepatology</i> , 2005 , 43, 434-41	13.4	257
26	Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. <i>Hepatology</i> , 2005 , 41, 753-60	11.2	188
25	Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. <i>Hepatology</i> , 2005 , 42, 282-92	11.2	254
24	Expression of chemokine and inhibitory receptors on natural killer cells: effect of immune activation and HIV viremia. <i>Journal of Infectious Diseases</i> , 2004 , 189, 1193-8	7	64
23	Cellular immune responses to the hepatitis B virus polymerase. <i>Journal of Immunology</i> , 2004 , 173, 5863-71	13.3	76
22	Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. <i>Contemporary Clinical Trials</i> , 2004 , 25, 472-92		151
21	A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. <i>Hepatology</i> , 2004 , 39, 188-96	11.2	568
20	Management of chronic hepatitis B. <i>Gastroenterology Clinics of North America</i> , 2004 , 33, 563-79, ix	4.4	2
19	Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. <i>Gastroenterology</i> , 2004 , 126, 1015-23; discussion 947	13.3	393

18	Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. <i>Hepatology</i> , 2003 , 38, 66-74	11.2	73
17	A rapid immunochromatographic assay for hepatitis B virus screening. <i>Journal of Viral Hepatitis</i> , 2003 , 10, 331-4	3.4	16
16	Progression of fibrosis in chronic hepatitis C. <i>Gastroenterology</i> , 2003 , 124, 97-104	13.3	319
15	Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. <i>Gastroenterology</i> , 2003 , 124, 352-60	13.3	109
14	Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. <i>Hepatology</i> , 2002 , 36, 1273-9	11.2	153
13	Hepatitis B e Antigen--the dangerous endgame of hepatitis B. <i>New England Journal of Medicine</i> , 2002 , 347, 208-10	59.2	24
12	Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers. <i>Journal of Viral Hepatitis</i> , 2001 , 8, 256-63	3.4	38
11	Transcription-mediated amplification is more sensitive than conventional PCR-based assays for detecting residual serum HCV RNA at end of treatment. <i>American Journal of Gastroenterology</i> , 2001 , 96, 2968-72	0.7	59
10	16 Hepatitis C virus and human immunodeficiency virus coinfection. <i>Biomedical Research Reports</i> , 2000 , 2, 315-328		
9	Long-term therapy of chronic hepatitis B with lamivudine. <i>Hepatology</i> , 2000 , 32, 828-34	11.2	275
8	Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. <i>Hepatology</i> , 1998 , 27, 213-22	11.2	279
7	10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. <i>Hepatology</i> , 1998 , 28, 1121-7	11.2	248
6	Predictive value of aminotransferase and hepatitis B virus DNA levels on response to interferon therapy for chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 1998 , 5, 171-8	3.4	34
5	Correlation between serum HCV RNA and aminotransferase levels in patients with chronic HCV infection. <i>Digestive Diseases and Sciences</i> , 1996 , 41, 2213-8	4	19
4	Effect of human immunodeficiency virus infection on hepatitis C virus infection in hemophiliacs. <i>Digestive Diseases and Sciences</i> , 1996 , 41, 1265-72	4	60
3	A young woman with cirrhosis: Autoimmune hepatitis vs. α_1 -antitrypsin deficiency. <i>Hepatology</i> , 1994 , 19, 1302-1306	11.2	4
2	Acute Viral Hepatitis2073-2111		
1	Viral Escape Mechanisms in Hepatitis C and the Clinical Consequences of Persistent Infection877-897		

